What is it about?
Immune checkpoint inhibitors are drugs that revolutionize oncology. However, the search for biomarkers regarding which patient we will use these drugs for continues. In this study, we investigated the predictive effect of ABO blood group, which can be easily obtained in our routine practice. We found that the presence of B antigen was associated with better survival.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Our study is the first to investigate the relationship between ABO blood group and immune checkpoint inhibitors.
Perspectives
If our results are supported by other studies, an easily accessible predictive biomarker will enter our routine practice.
Assoc. Prof. Yakup Ergun
Read the Original
This page is a summary of: Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors, Cancer Biomarkers, May 2022, IOS Press,
DOI: 10.3233/cbm-210455.
You can read the full text:
Contributors
The following have contributed to this page
